Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder

Biological Psychiatry

Volumn 65, Issue 9, 2009, Pages 792-800

  Price, Rebecca B ^a,c   Shungu, Dikoma C ^b   Mao, Xiangling ^b   Nestadt, Paul ^a   Kelly, Chris ^a   Collins, Katherine A ^a   Murrough, James W ^a   Charney, Dennis S ^a   Mathew, Sanjay J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Depression; GABA; glutamate; magnetic resonance; spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; GLUTAMIC ACID; GLUTAMINE;

ADULT; ANTERIOR CINGULATE CORTEX; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR DEPRESSION; MALE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; BRAIN; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; OCCIPITAL LOBE;

EID: 63449086038     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.10.025     Document Type: Article

References (50)

1. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56 (1999) 1043-1047
2. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.-T., Appel M., Rothman D.L., et al. Subtype-specific alterations of c-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61 (2004) 705-713
3. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., et al. Reduction in occipital cortex GABA concentrations in medication free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61 (2007) 806-812
4. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., Matthews P.M., et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11 (2008) 255-260
5. Hasler G., Van der Veen J., Tuonis T., Meyers N., Shen J., and Drevets W.C. Reduced prefrontal glutamate/glutamine and c-aminobutryric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64 (2007) 193-200
6. aan het Rot M., Charney D.S., and Mathew S.J. Intravenous ketamine for treatment-resistant major depressive disorder. Prim Psychiatry 15 (2008) 39-47
7. Sanacora G., Zarate C.A., Krystal J.H., and Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7 (2008) 426-437
8. Zarate Jr. C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006) 856-864
9. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., et al. Treatment resistant depression: Methodological overview and operational criteria. Eur Neuropsychopharmacol 9 (1999) 83-91
10. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53 (2003) 649-659
11. Thase M.E., and Rush A.J. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 suppl 13 (1997) 23-29
12. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry 163 (2006) 1531-1541
13. Ressler K.J., and Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nat Neurosci 10 (2007) 1116-1124
14. First M.B., Spitzer R.L., Williams J.B.W., and Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (1995), New York Psychiatric Institute, New York
15. Sackeim H.A. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62 suppl 16 (2001) 10-17
16. Prudic J., Haskett R.F., Mulsant B., Malone K.M., Pettinati H.M., Stephens S., et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 153 (1996) 985-992
17. Posternak M.A., and Zimmerman M. How accurate are patients in reporting their antidepressant treatment history?. J Affect Disord 75 (2003) 115-124
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
19. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician-Rating (QIDS-C), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54 (2003) 573-583
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
21. Sheehan D.V. The Anxiety Disease (1983), Scribner's, New York
22. Hollingshead A.B. Four Factor Index of Social Position (1975), Yale University, New Haven, CT
23. Weissman M.M., Wickramaratne P., Adams P., Wolk S., Verdeli H., and Olfson M. Brief screening for family psychiatric history: The family history screen. Arch Gen Psychiatry 57 (2000) 675-682
24. Rothman D.L., Petroff O.A.C., Behar K.L., and Mattson R.H. Localized 1H NMR measurements of g-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 90 (1993) 5662-5666
25. Sailasuta N., LeRoux P., Hurd R., Wang P., Sachs N., and Ketter T.A. Detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers at 3 T. Proc Int Soc Mag Reson Med 6 (2001) 1011
26. Shungu D.C., Mao X., and Kegeles L.S. Evaluation of GABA detection sensitivity gains achieved with an 8-channel phased-array head coil at 3.0 T in the human dorsolateral prefrontal cortex using the J-editing technique. Proc Int Soc Mag Reson Med 14 (2006) 488
27. Brown M.A. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med 52 (2004) 1207-1213
28. Marshall I., Bruce S.D., Higinbotham J., MacLullich A., Wardlaw J.M., Ferguson K.J., et al. Choice of spectroscopic lineshape model affects metabolite peak areas and area ratios. Magn Reson Med 44 (2000) 646-649
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1988), Lawrence Erlbaum Associates, Hillsdale, NJ
30. Menard S. Applied Logistic Regression Analysis: Sage University Series on Quantitative Applications in the Social Sciences (1995), Sage, Thousand Oaks, CA
31. Drevets W.C. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11 (2001) 240-249
32. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46 (1999) 1375-1387
33. Sargent P.A., Kjaer K.H., Bench C.J., Rabiner E.A., Messa C., Meyer J., et al. Brain serotonin-1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry 57 (2000) 174-180
34. Saxena S., Brody A.L., Ho M.L., Alborzian S., Maidment K.M., Zohrabi N., et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 59 (2002) 250-261
35. Petty F., Kramer G.L., Gullion C.M., and Rush A.J. Low plasma γ-aminobutyric acid levels in male patients with depression. Biol Psychiatry 32 (1992) 354-363
36. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., and Ogawa N. Cerebrospinal fluid γ-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 17 (1982) 877-883
37. Roy A., Dejong J., and Ferraro T. CSF GABA in depressed patients and normal controls. Psychol Med 21 (1991) 613-618
38. Charney D.S., and Manji H.K. Life stress, genes, and depression: Multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 225 (2004) re5
39. Sanacora G., Rothman D.L., Mason G.F., and Krystal J.H. Clinical studies implicating glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 1003 (2003) 292-308
40. Batra N.A., Seres-Mailo J., Hanstock C., Seres P., Khudabux J., Bellavance F., et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry 63 (2008) 1178-1184
41. Mirza Y., Tang J., Russell A., Banerjee S.P., Bhandari R., Ivey J., et al. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 43 (2004) 341-348
42. Rosenberg D.R., Macmaster F.P., Mirza Y., Smith J.M., Easter P.C., Banerjee S.P., et al. Reduced anterior cingulate glutamate in pediatric major depression: A magnetic resonance spectroscopy study. Biol Psychiatry 58 (2005) 700-707
43. Sanacora G., Mason G.F., Rothman D.L., and Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159 (2002) 663-665
44. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., and Sanacora G. Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. [published online ahead of print September 30]. Mol Psychiatry (2008)
45. Mathew S.J., Manji H.K., and Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33 (2008) 2080-2092
46. Kegeles L.S., Mao X., Dyke J., Gonzales R., Soones T.N., and Shungu D.C. Test-retest reliability of dorsolateral prefrontal cortical GABA measurement using an 8-channel phased-array head coil with the J-editing technique at 3T. Proc Int Soc Mag Reson Med 14 (2006) 489
47. Pollack M.H., Jensen J.E., Simon N.M., Kaufman R.E., and Renshaw P.F. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 739-743
48. Goddard A.W., Mason G.F., Almai A., Rothman D.L., Behar K.L., Petroff O.A., et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58 (2001) 556-561
49. Goddard A.W., Mason G.F., Appel M., Rothman D.L., Gueorguieva R., Behar K.L., and Krystal J.H. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 161 (2004) 2186-2193
50. Behar K.L., Rothman D.L., Petersen K.F., Hooten M., Delaney R., Petroff O.A., et al. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 156 (1999) 952-954